Molecular Validation of PACE4 as a Target in Prostate Cancer

Abstract excerpt

Prostate cancer remains the single most prevalent cancer in men. Standard therapies are still limited and include androgen ablation that initially causes tumor regression. However, tumor cells eventually relapse and develop into a hormone-refractory prostate cancer. One of the current challenges in this disease is to define new therapeutic targets, which have been virtually unchanged in the past 30 years. Recent...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Prostate Cancer Treatment and Research
• Share to Protease and Inhibitor Mechanisms
• Share to Ubiquitin and proteasome pathways